U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H14F3N3O3S
Molecular Weight 397.372
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DERACOXIB

SMILES

COC1=C(F)C=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(N)(=O)=O)C(F)F

InChI

InChIKey=WAZQAZKAZLXFMK-UHFFFAOYSA-N
InChI=1S/C17H14F3N3O3S/c1-26-16-7-2-10(8-13(16)18)15-9-14(17(19)20)22-23(15)11-3-5-12(6-4-11)27(21,24)25/h2-9,17H,1H3,(H2,21,24,25)

HIDE SMILES / InChI

Molecular Formula C17H14F3N3O3S
Molecular Weight 397.372
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/21985349

Deracoxib (trade name Deramaxx, Novartis) is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine for the control of postoperative pain and inflammation associated with orthopedic and dental surgery and for the control of pain and inflammation associated with osteoarthritis in dogs. Data indicate that deracoxib inhibits the production of PGE1 and 6-keto PGF1 by its inhibitory effects on prostaglandin biosynthesis. Deracoxib was shown to have antitumor effect against transitional cell carcinoma of the urinary bladder.

CNS Activity

Curator's Comment: Small animals. Some NSAIDs have also been associated with CNS signs such as seizures and coma at higher doses. The more common drugs that can cause such a CNS effect include carprofen, deracoxib, naproxen, etodolac, meloxicam, and indomethacin.

Originator

Curator's Comment: Deramaxx was developed by Novartis for dogs but was discovered by G.D. Searle

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Osteosarcoma cell growth
150.0 µM [IC50]
Target ID: O19183
Gene ID: 791253.0
Gene Symbol: PTGS2
Target Organism: Equus caballus (Horse)
0.39 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
DERAMAXX (deracoxib)

Approved Use

Osteoarthritis pain and inflammation

Launch Date

2002
Palliative
DERAMAXX (deracoxib)

Approved Use

For postoperative orthopedic pain and inflammation

Launch Date

2002
Palliative
DERAMAXX (deracoxib)

Approved Use

For postoperative dental pain and inflammation

Launch Date

2002
PubMed

PubMed

TitleDatePubMed
Determination of deracoxib in feline plasma samples using high performance liquid chromatography.
2005 May 5
Nonsteroidal antiinflammatory drugs: a review.
2005 Sep-Oct
Effects of deracoxib and aspirin on serum concentrations of thyroxine, 3,5,3'-triiodothyronine, free thyroxine, and thyroid-stimulating hormone in healthy dogs.
2006 Apr
Cyclooxygenase expression and prostanoid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal anti-inflammatory drugs.
2008 Apr
Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006).
2008 Jul 1
Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs.
2009 Aug
Effect of nonsteroidal anti-inflammatory drugs with varied cyclooxygenase-2 selectivity on cyclooxygenase protein and prostanoid concentrations in pyloric and duodenal mucosa of dogs.
2009 Oct
Use of deracoxib during intense rehabilitation exercises.
2010
Randomised controlled clinical trial for the use of deracoxib during intense rehabilitation exercises after tibial plateau levelling osteotomy.
2010
Proximal duodenal perforation in three dogs following deracoxib administration.
2010 Jul-Aug
In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.
2010 Jun
Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs.
2010 Mar
Characterization and modulation of canine mast cell derived eicosanoids.
2010 May 15
Spontaneous pneumothorax in a dog secondary to Dirofilaria immitis infection.
2010 Nov
Patents

Sample Use Guides

Osteoarthritis Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, as needed. Postoperative Orthopedic Pain and inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration. Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.
Route of Administration: Oral
In Vitro Use Guide
Deracoxib was used for the treatment of Canine bone marrow derived cultured mast cells (cBMCMCs) at the concentration 1uM and incubated for 24 h to strongly inhibit PGD2 and PGE2 production.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:42:42 GMT 2023
Edited
by admin
on Fri Dec 15 15:42:42 GMT 2023
Record UNII
VX29JB5XWV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DERACOXIB
GREEN BOOK   INN   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
4-(3-(DIFLUOROMETHYL)-5-(3-FLUORO-4-METHOXYPHENYL)-1H-PYRAZOL-1-YL)BENZENESULFONAMIDE
Systematic Name English
DERACOXIB [MI]
Common Name English
NSC-758935
Code English
deracoxib [INN]
Common Name English
Deracoxib [WHO-DD]
Common Name English
DERACOXIB [GREEN BOOK]
Common Name English
SC-59046
Code English
DERACOXIB [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
CFR 21 CFR 520.538
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL28636
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
INN
7789
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
FDA UNII
VX29JB5XWV
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
DAILYMED
VX29JB5XWV
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
USAN
II-36
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
CAS
169590-41-4
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
PUBCHEM
3058754
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
WIKIPEDIA
DERACOXIB
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
MERCK INDEX
m4185
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY Merck Index
CHEBI
73032
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
SMS_ID
100000087755
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
EVMPD
SUB01594MIG
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
MESH
C471996
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
NSC
758935
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
EPA CompTox
DTXSID4045975
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
RXCUI
356834
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY RxNorm
DRUG BANK
DB11395
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
NCI_THESAURUS
C73031
Created by admin on Fri Dec 15 15:42:42 GMT 2023 , Edited by admin on Fri Dec 15 15:42:42 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY